Pharmaceutical

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).

Jun 3, 2025 - 06:00
Zymeworks’ zanidatamab gains approval in China for biliary tract cancer
China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract cancer (BTC).
Read the original article

Tags:

Previous Article

ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

Next Article

Unveiling the Secret Mechanisms of Ice Formation: How Ice Builds Layer by Layer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Health tech’s 2024 hiring outlook: Balance tips toward employers

STAT+: Health tech’s 2024 hiring outlook: Balance tips ...

Jan 4, 2024

Pfizer’s first-ever bispecific antibody Elrexfio holds promise in multiple myeloma

Pfizer’s first-ever bispecific antibody Elrexfio holds ...

Aug 26, 2023

Forbion European Acquisition and enGene sign merger deal

Forbion European Acquisition and enGene sign merger deal

May 18, 2023